POSTER: MCL-553 Glofitamab Induces High Response Rates and Durable Remissions in Patients With Heavily Pretreated Relapsed/Refractory (R/R) Mantle Cell Lymphoma (MCL), Including Those With a Poor Prognosis: Subgroup Results From a Phase 1/2 Trial
Year: 2025
Type: article
Authors: Tycel Phillips, Marek Trneny, Carmelo Carlo-Stella, Jan Zaucha, Tomasz Wrobel, Fritz Offner, Michael Dickinson, Monica Tani, Michael Crump, Nancy L. Bartlett, Joaquin Martinez-Lopez, Paolo Corradini, Estefania Mulvihill, Alessia Bottos, Derrick Kaufman, James Relf, Fabiola Bene Tchaleu, Alexandra Bazeos, Linda Lundberg, Franck Morschhauser
Language: English
Subfield: Pathology and Forensic Medicine
Field: Medicine
Domain: Health Sciences
Open Access status: closed
OpenAlex ID: W4413810217